Qinhai Ma

1.8k total citations · 1 hit paper
39 papers, 1.2k citations indexed

About

Qinhai Ma is a scholar working on Infectious Diseases, Immunology and Epidemiology. According to data from OpenAlex, Qinhai Ma has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 13 papers in Immunology and 11 papers in Epidemiology. Recurrent topics in Qinhai Ma's work include SARS-CoV-2 and COVID-19 Research (12 papers), interferon and immune responses (11 papers) and Influenza Virus Research Studies (9 papers). Qinhai Ma is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (12 papers), interferon and immune responses (11 papers) and Influenza Virus Research Studies (9 papers). Qinhai Ma collaborates with scholars based in China, Macao and United States. Qinhai Ma's co-authors include Zifeng Yang, Jin Zhao, Haiming Jiang, Jun Dai, Jicheng Huang, Kui Zheng, Chufang Li, Weiqi Pan, Yongxia Shi and Runfeng Li and has published in prestigious journals such as British Journal of Pharmacology, Frontiers in Immunology and Molecules.

In The Last Decade

Qinhai Ma

35 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

2020 495 citations Runfeng Li, Yunlong Hou et al. Pharmacological Research profile →

Peers

Countries citing papers authored by Qinhai Ma

Since Specialization

Citations

This map shows the geographic impact of Qinhai Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qinhai Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qinhai Ma more than expected).

Fields of papers citing papers by Qinhai Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qinhai Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qinhai Ma. The network helps show where Qinhai Ma may publish in the future.

Co-authorship network of co-authors of Qinhai Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Qinhai Ma. A scholar is included among the top collaborators of Qinhai Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qinhai Ma. Qinhai Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Post-influenza bacterial infection: mechanisms of pathogenesis and advances in therapeutic strategies 2025 ·Frontiers in Microbiology ·Biao Lei, Shun Wang, Linzhong Yu, Qinhai Ma	0
2	Multi-dimensional PK-PD insights into Lianhua Qingwen's formula compatibility 2025 ·Journal of Ethnopharmacology ·(unknown), Sheng Chen, Xueqin Chen, Qinhai Ma, (unknown), (unknown), Y. Thomas Hou, Wei Feng, Chunyan Zhu, (unknown), A. Ding, B. Z. Dai, Xiaoya Wang, (unknown), C. F. Jeff Wu, Zhenhua Jia	0
3	PEBL, a component-based Chinese medicine, reduces virus-induced acute lung injury by targeting FXR to decrease ACE2 levels 2025 ·Journal of Advanced Research ·Liling Yang, (unknown), Junshan Liu, Guangli Yang, (unknown), (unknown), (unknown), (unknown), Wei Li, Jiayang He, Huihui Cao, Qinhai Ma, Linzhong Yu, Zibin Lu	1
4	Dihydrotanshinone I targets the spike N-terminal domain to inhibit SARS-CoV-2 entry and spike-induced inflammation 2025 ·Phytomedicine ·Chan Yang, (unknown), Jinshen Wang, Haibin Su, (unknown), (unknown), Xiaoyan Pan, Haobin Li, Peng Zheng, Yinghua Chen, Yan Wu, Qinhai Ma, Guodong Hu, Shuwen Liu	0
5	Design, synthesis and activity evaluation of 4-(quinoline-2-yl)aniline derivatives as SARS-CoV‑2 main protease inhibitors 2025 ·Bioorganic & Medicinal Chemistry ·(unknown), Hui Meng, (unknown), Yan Gong, Gao Tu, (unknown), (unknown), Jian‐Lin Wu, Chunhua Ma, Qinhai Ma, Xiaojun Yao	1
6	Glycyrrhetinic acid blocks SARS‐CoV‐2 infection by activating the cGAS‐STING signalling pathway 2024 ·British Journal of Pharmacology ·(unknown), Qinhai Ma, (unknown), (unknown), Caisheng Wu, (unknown), (unknown), (unknown), Zhenhua Jia	4
7	Liushen Wan alleviates the virulence and inflammation of Staphylococcus aureus via NLRP3 inflammasome and TLR2-NF-κB/p38 MAPK signaling pathways 2024 ·International Immunopharmacology ·Yu Song, Qinhai Ma, Jing Luo, Zifeng Yang, Jiqiang Li, Jin Zhao	1
8	Liang–Ge–San protects against viral infection-induced acute lung injury through inhibiting α7nAChR-mediated mitophagy 2024 ·Phytomedicine ·(unknown), Zibin Lu, Bing Chen, Xuemei He, Wei Zhao, Huihui Cao, Yuhua Li, Peng Guo, (unknown), Qinhai Ma, Linzhong Yu, Junshan Liu	4
9	SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern 2023 ·Frontiers in Immunology ·Qinhai Ma, Man Li, Lin Ma, (unknown), (unknown), Huiling Zhong, (unknown), Yongsheng Wang, (unknown), (unknown), Linping Wu, Jianmin Guo, Wei Yang, Zifeng Yang, Biliang Zhang	4
10	Preclinical Study of ZSP1273, a Potent Antiviral Inhibitor of Cap Binding to the PB2 Subunit of Influenza A Polymerase 2023 ·Pharmaceuticals ·Xiaoxin Chen, Qinhai Ma, Manyu Zhao, Yuqin Yao, Qianru Zhang, Miao Liu, Zifeng Yang, Wenbin Deng	12
11	Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro 2022 ·Chinese Medicine ·Qinhai Ma, Biao Lei, Ruihan Chen, Bin Liu, Wencong Lu, Haiming Jiang, (unknown), (unknown), Yutao Wang, Lu Zhang, Qiaoyan Chen, Zheng‐Xiang Li, Zifeng Yang	9
12	Investigating the effects of Liushen Capsules (LS) on the metabolome of seasonal influenza: A randomized clinical trial 2022 ·Frontiers in Pharmacology ·Qinhai Ma, (unknown), Jing Zeng, Biao Lei, Feng Ye, (unknown), Zhengtu Li, Yangqing Zhan, Bin Liu, (unknown), Zifeng Yang	1
13	Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2 2021 ·Journal of Ethnopharmacology ·Qinhai Ma, Yuqi Xie, Zhoulang Wang, Biao Lei, Ruihan Chen, Bin Liu, Haiming Jiang, Yutao Wang, Qingquan Liu, Zifeng Yang	26
14	Liu Shen Wan inhibits influenza virus-induced secondary Staphylococcus aureus infection in vivo and in vitro 2021 ·Journal of Ethnopharmacology ·Jin Zhao, Yutao Wang, Xiaodong Huang, Qinhai Ma, (unknown), Xiao Y. Wu, Hongxia Zhou, Yunceng Weng, Zifeng Yang, Xinhua Wang	21
15	San Wu Huangqin decoction regulates inflammation and immune dysfunction induced by influenza virus by regulating the NF-κB signaling pathway in H1N1-infected mice 2020 ·Journal of Ethnopharmacology ·Qinhai Ma, (unknown), Luo Jia-bo	27
16	Liu Shen Wan inhibits influenza a virus and excessive virus-induced inflammatory response via suppression of TLR4/NF-κB signaling pathway in vitro and in vivo 2020 ·Journal of Ethnopharmacology ·Qinhai Ma, Wenbo Huang, Jin Zhao, Zifeng Yang	55
17	Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) breakdown → 2020 ·Pharmacological Research ·Runfeng Li, Yunlong Hou, Jicheng Huang, Weiqi Pan, Qinhai Ma, Yongxia Shi, Chufang Li, Jin Zhao, Zhenhua Jia, Haiming Jiang, Kui Zheng, Shuxiang Huang, Jun Dai, Zheng‐Xiang Li, Xiaotao Hou, Lin Wang, Nanshan Zhong, Zifeng Yang	495
18	Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway 2020 ·Phytomedicine ·Qinhai Ma, Runfeng Li, Weiqi Pan, Wenbo Huang, Bin Liu, Yuqi Xie, Zhoulang Wang, Chufang Li, Haiming Jiang, Jicheng Huang, Yongxia Shi, Jun Dai, Kui Zheng, Xiaobo Li, Hui Min, Li Fu, Zifeng Yang	84
19	Antitumorpharmacological mechanism of the oral liquid of Poriacocos polysaccharide 2017 ·Journal of Ethnopharmacology ·(unknown), Qinhai Ma, (unknown), (unknown), (unknown), Luo Jia-bo	26
20	Concurrent quantification and comparative pharmacokinetic analysis of bioactive compounds in the Herba Ephedrae-Semen Armeniacae Amarum herb pair 2015 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), Feilong Chen, (unknown), (unknown), Qinhai Ma, Ying Xie, Qingfa Tang, Luo Jia-bo	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact